Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study.
Meike W Vernooij, Mendel D M Haag, Aad van der Lugt...
https://pubmed.ncbi.nlm.nih.gov/19364926/Actively Recruiting
Led by Xijing Hospital · Updated on 2026-07-30
3000
Participants Needed
16
Research Sites
N/A
Total Duration
This research aims to observe the effects of different antithrombotic drugs on patients over 40 years old who have had an ischemic stroke and also have cerebral microbleeds. Cerebral microbleeds are small brain vessel injuries causing deposits of blood breakdown products, which can increase the risk of brain bleeding. The study also uses proteomic methods to find blood markers that might predict how these patients will recover. Participants will be observed for one year after their stroke while using various antithrombotic drugs, which are commonly prescribed to prevent further strokes but may raise the risk of brain bleeding in these patients. The study involves tracking changes in cerebral microbleeds and stroke recurrence, along with analyzing blood samples to identify proteins linked to patient outcomes. During the one-year study period, participants will have their brain microbleeds monitored and stroke recurrence rates recorded. Blood tests will be done to explore protein markers that could help predict prognosis. The main outcome measured is the increase in cerebral microbleeds one year after stroke onset, with secondary outcomes including stroke recurrence and incidence of brain hemorrhage. Safety and progress will be closely followed throughout the study.
CONDITIONS
Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds
W
Wen Jiang, Ph.D
F
Fang Yang, Ph.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Xijing Hospital
Lead Sponsor
Ankang Central Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 year
Participants are monitored for one year to assess the effects of different antithrombotic drugs on their brain microbleeds and stroke recurrence.
Regular assessments and blood tests throughout the year
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Meike W Vernooij, Mendel D M Haag, Aad van der Lugt...
https://pubmed.ncbi.nlm.nih.gov/19364926/R N K Nandigam, A Viswanathan, P Delgado...
https://pubmed.ncbi.nlm.nih.gov/19001544/Ashkan Shoamanesh, Robert G Hart, Stuart J Connolly...
https://pubmed.ncbi.nlm.nih.gov/33074284/Yajun Cheng, Yanan Wang, Quhong Song...
https://pubmed.ncbi.nlm.nih.gov/31616992/Andreas Charidimou, Gregoire Boulouis, Sara Shams...
https://pubmed.ncbi.nlm.nih.gov/28566143/Kazumi Kimura, Junya Aoki, Kensaku Shibazaki...
https://pubmed.ncbi.nlm.nih.gov/23887835/Shuping Liu, Chengyan Li
https://pubmed.ncbi.nlm.nih.gov/26272868/Charlotte Cordonnier, Rustam Al-Shahi Salman, Joanna Wardlaw
https://pubmed.ncbi.nlm.nih.gov/17322562/Ashkan Shoamanesh, Shenqiang Yan, Andreas Charidimou
https://pubmed.ncbi.nlm.nih.gov/26441822/Xijing Hospital
Lead Sponsor
Ankang Central Hospital
Collaborating Sponsor